Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings
CNBC Earnings
Barrons Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

Stocktwits
MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-

Climb Bio, Inc. Common Stock | CLYM

AI Analysis of Climb Bio, Inc. Common Stock

Investors didn't show much interest in one Climb Bio way or another today. It hasn't moved too much today but is slightly down, it lost -0.39% since yesterday.

Currently CLYM isn't at a clear support/resistance line that seems tradable. But let's also consider momentum! Climb Bio has had a nice run over the last year and provided good returns to shareholders. Over the previous year, the asset has grown 782.07 percent which isn't too bad. It may find some support around the $11.96 price level in the near term.


Last analyzed on 2026-07-23

Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-